Axitinib plus Pembrolizumab Is Well Tolerated and Exhibits Antitumor Activity in Treatment-Naïve Patients with Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.